Elevance Health stock at EUR 376.05 with P/ E 18.6

Published on 10/12/2026 at 16:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Elevance Health stock costs EUR 376.05 on October 12, 2026 with P/E 18.6. Results are due October 21, 2026 at 6:00 a.m. EDT.

Key points in brief

Elevance Health stock was trading at EUR 376.05 at Lang & Schwarz on October 12, 2026 at 4:41 p.m. CEST.
The stock's 52-week range was USD 274.84 to USD 436.24, with market capitalization at USD 90.6 billion.
Barclays raised its target from USD 457 to USD 469 on October 7, 2026.
Third-quarter 2026 results are scheduled for October 21, 2026 at 6:00 a.m. EDT.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at EUR 376.05 at Lang & Schwarz on October 12, 2026 at 4:41 p.m. CEST, while its P/E ratio stood at 18.6. The euro quote places the US health insurer below its USD 436.24 52-week high and above its USD 274.84 low.

Price sits below yearly high

The spread between the 52-week high and low is USD 161.40, giving the stock a broad trading frame for the current quote. Elevance Health had a market capitalization of USD 90.6 billion and volume of 155,984 shares as of October 12, 2026, versus average volume of 1,206,248 shares.

The home-market quote was USD 417.57 at 10:49 a.m. EDT on October 12, 2026, during the NYSE session. The US-dollar price and the euro quote represent separate venues and currencies.

Barclays target reaches USD 469

Markets Insider reported on October 7, 2026 that Barclays raised its Elevance Health price target from USD 457 to USD 469 and kept an Overweight rating. The target increase of USD 12 gives the analyst view a clear numerical counterpoint to the current market valuation.

Barclays made the change as part of a third-quarter earnings preview and cited Medicaid exposure alongside risks for hospital earnings. The statement places the target discussion ahead of the company's next scheduled report.

Comparison with peers

Elevance Health: , P/E 18.6, market capitalization USD 90.6 billion
Humana (NYSE, USD): minus 1.87 percent, P/E 40.39, market capitalization USD 50.9 billion
Cigna (NYSE, USD): minus 0.05 percent, P/E 11.71, market capitalization USD 74.6 billion

Results date is October 21

Elevance Health said on October 5, 2026 that it will release third-quarter 2026 results on October 21, 2026 at 6:00 a.m. EDT and hold its conference call at 8:30 a.m. EDT. The date is the next scheduled company event for the stock.

For investors, the key measurable markers are the EUR 376.05 euro quote, the USD 90.6 billion market capitalization and the USD 469 Barclays target. Together they frame the stock ahead of the October results date without mixing the euro trading price with US-dollar valuation figures.

Trading range remains wide

The stock's USD 274.84 to USD 436.24 52-week range shows that the current level remains materially below the upper boundary while staying above the lower boundary. The latest Lang & Schwarz quote was EUR 376.05 on October 12, 2026 at 4:41 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.